Oruka Therapeutics, Inc. (ORKA) FY2025 10-K Annual Report
Oruka Therapeutics, Inc. (ORKA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Oruka Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Clinical-stage biopharma developing novel monoclonal antibodies for psoriasis and inflammatory/immunology indications
- • New emphasis: Acquisition and rebranding of Pre-Merger Oruka in 2024, launching dual lead programs ORKA-001 and ORKA-002 targeting IL-23p19 and IL-17A/F
- • Strategic shift: Leveraging advanced antibody engineering for extended half-life, aiming for reduced dosing frequency (up to twice yearly) and improved efficacy vs standard-of-care
- • Quantitative highlight: Initiated multiple Phase 2 trials; ORKA-001 Phase 2a enrolled 84 patients, Phase 2b expected to enroll 160 patients; ORKA-002 Phase 2 planned to enroll 160 patients
- • Noteworthy fact: ORKA-001 demonstrated ~100-day half-life in Phase 1; ORKA-002 showed ~75-80 day half-life, supporting potential twice-yearly dosing schedules
Management Discussion & Analysis
- • No revenue generated; net loss $105.4M for 2025; accumulated deficit $189.2M as of December 31, 2025
- • Operating cash flow negative $88.2M; cash, equivalents, and marketable securities $479.6M at year-end
- • No segments reporting revenue; focus on clinical-stage pipeline with lead programs ORKA-001 and ORKA-002 in Phase 1/2 trials
- • Capital raised $275M in Pre-Closing Financing; $20.5M transaction costs reduce equity; no dividends or buybacks disclosed
- • Management expects losses to continue; Phase 2 data releases anticipated in 2026-2027; FDA timelines uncertain, key risk regulatory review duration
Risk Factors
- • FDA regulatory delays risk impacting approval timeline for product candidates ORKA-001 and ORKA-002 amid ongoing Phase 1 and Phase 2 trials
- • Geopolitical tensions and elevated interest rates contributing to market volatility that may hinder timely capital raises for ongoing clinical development
- • Dependency on third-party manufacturers and single-source suppliers for drug delivery devices poses risk of supply interruptions or delayed regulatory approvals
- • Competitive pressure from larger biopharma firms with greater resources and existing immunology programs threatens market penetration for Oruka’s candidates
- • High dilution risk from recent equity raises totaling over 16 million shares and $38.9 million net proceeds under at-the-market offering through March 2026
Oruka Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$105M
▼ -25.9% YoY
ROE
-22.3%
▼ -44bp YoY
Total Assets
$489M
▲ +23.4% YoY
Operating Cash Flow
-$88M
▼ -52.5% YoY
Source: XBRL data from Oruka Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Oruka Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.